Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06554847
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-12
Brief Title:
Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Multi-Centered Randomized Double-Blinded Placebo-Controlled Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of 611Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody When Used In Combination With Topical Corticosteroid Treatment TCS in Participants With Moderate to Severe Atopic Dermatitis
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a randomized double-blind placebo-controlled parallel-group study to evaluate the safety and efficacy of 611 when used in combination with topical corticosteroid TCS treatment compared with placebo in combination with TCS treatment for moderate-to-severe atopic dermatitis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None